- Home
- ENSG vs BBIO Comparison
ENSG vs BBIO Comparison
Compare ENSG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSG
- BBIO
- Stock Information
- Founded
- ENSG 1999
- BBIO 2015
- Country
- ENSG United States
- BBIO United States
- Employees
- ENSG N/A
- BBIO N/A
- Industry
- ENSG Hospital/Nursing Management
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ENSG Health Care
- BBIO Health Care
- Exchange
- ENSG Nasdaq
- BBIO Nasdaq
- Market Cap
- ENSG 10.5B
- BBIO 10.4B
- IPO Year
- ENSG 2007
- BBIO 2019
- Fundamental
- Price
- ENSG $180.89
- BBIO $67.46
- Analyst Decision
- ENSG Buy
- BBIO Strong Buy
- Analyst Count
- ENSG 4
- BBIO 19
- Target Price
- ENSG $194.00
- BBIO $74.79
- AVG Volume (30 Days)
- ENSG 506.3K
- BBIO 2.6M
- Earning Date
- ENSG 11-03-2025
- BBIO 10-29-2025
- Dividend Yield
- ENSG 0.14%
- BBIO N/A
- EPS Growth
- ENSG 35.03
- BBIO N/A
- EPS
- ENSG 5.59
- BBIO N/A
- Revenue
- ENSG $4,829,467,000.00
- BBIO $353,780,000.00
- Revenue This Year
- ENSG $19.99
- BBIO $123.32
- Revenue Next Year
- ENSG $10.84
- BBIO $73.46
- P/E Ratio
- ENSG $32.16
- BBIO N/A
- Revenue Growth
- ENSG 17.55
- BBIO 62.46
- 52 Week Low
- ENSG $118.73
- BBIO $21.72
- 52 Week High
- ENSG $194.00
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- ENSG 50.62
- BBIO 70.54
- Support Level
- ENSG $175.94
- BBIO $60.55
- Resistance Level
- ENSG $185.31
- BBIO $64.44
- Average True Range (ATR)
- ENSG 5.85
- BBIO 3.28
- MACD
- ENSG -0.92
- BBIO 0.32
- Stochastic Oscillator
- ENSG 31.36
- BBIO 86.54
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.